Before a prescription
A tirzepatide prescription starts with your whole story

You don’t need a perfect question to begin. The exact medicine, your health and a plan for follow-up are good places to start.
Which medicine are we talking about?
Tirzepatide is an ingredient name. Zepbound (tirzepatide) and Mounjaro (tirzepatide) are FDA-approved products with different labeled uses. A compounded tirzepatide preparation is not FDA-approved.
The Zepbound label covers weight management in adults with obesity, or overweight with a weight-related health problem, alongside a reduced-calorie diet and increased physical activity. There’s a sleep-apnea use too: adults must have obesity and obstructive sleep apnea that’s moderate to severe. The Mounjaro label covers type 2 diabetes and lowering heart attack and stroke risk in high-risk adults with type 2 diabetes.
A good opening question is: what problem is this prescription meant to address? That gives the conversation a purpose beyond a medicine’s name.
What does the prescriber need to know?
The label flags relevant health history, including medullary thyroid cancer in the family, serious stomach problems, pancreas or gallbladder trouble and diabetic eye disease. Previous serious allergies matter too. Pregnancy plans, birth control pills and upcoming procedures also belong in the discussion.
Your other medicines are part of that picture, including diabetes treatment. There’s room to ask why a detail matters or what information is still missing. A review may lead to more questions or a decision not to prescribe.
There’s no need to arrive with a polished medical summary. The side-effects story explains some of the warnings behind these questions.
How will follow-up work around my day?
It helps to know who can respond between visits. Where does a new symptom go? Who handles a routine treatment question? What happens if continuing becomes difficult?
Stopping deserves a conversation too. In a weight-management trial, adults first completed 36 weeks on tirzepatide, losing weight on average. Those switched to placebo regained weight on average over the next 52 weeks. That finding makes planning useful; it doesn’t decide anyone’s treatment length.
A named route for help is more useful than “we’ll see.” The right arrangement needs to come from the people providing your care.
What if a compounded preparation comes up?
FDA explains that it does not check compounded drugs for safety, effectiveness or quality before marketing. Sharing an ingredient with an approved product doesn’t establish that another preparation is equivalent.
There are legal limits too. FDA’s compounding policy explains the shortage-related restrictions. A prescription alone doesn’t settle every requirement.
Useful questions include why this preparation is being considered for you, what it contains and how concerns will be handled. Those answers belong with the licensed prescriber.